Sign In
Buy MRNA
$59.35
-4.62 (-7.22%)
At Close: Jun 22, 2026
Should You Buy Moderna Before Aug. 5?
06:10pm, Monday, 22'nd Jun 2026
Investors flocked to Moderna during early pandemic days as its coronavirus vaccine delivered blockbuster revenue. Since, times have been tough for Moderna, but the company may have reached an importan
Moderna Has Some Key Approvals Ahead. Is the Stock a Buy?
07:30am, Saturday, 20'th Jun 2026
Modera grew revenue by 260% year over year in the first quarter. The company is trying its mRNA platform in oncology vaccines.
MRNA Up as Influenza Vaccine Wins Unanimous FDA Advisory Panel Backing
09:06am, Friday, 19'th Jun 2026
Moderna stock gains 3.5% after FDA advisory panel votes 9-0 that mFlusiva's benefits outweigh risks in influenza prevention in older adults, ahead of an Aug. 5 decision.
FDA Votes in Favor of Benefit-Risk Profile for Moderna's Flu Vaccine
04:23pm, Thursday, 18'th Jun 2026
Moderna said the FDA's Vaccines and Related Biological Products Advisory Committee voted unanimously that the benefits of the vaccine, mRNA-1010, exceed the risks for the prevention of flu in adults 5
FDA Prescription Drug User Fee Act (PDUFA) goal date remains August 5, 2026 CAMBRIDGE, MA / ACCESS Newswire / June 18, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Ad
US FDA advisers vote in favor of Moderna's flu vaccine
02:48pm, Thursday, 18'th Jun 2026
The U.S. Food and Drug Administration's advisers on Thursday backed approval of Moderna's flu vaccine in adults aged 50 and older, saying its benefits outweigh the risks.
Moderna's mRNA flu vaccine faces FDA advisory panel scrutiny
06:01am, Thursday, 18'th Jun 2026
The U.S. Food and Drug Administration's advisory panel is set to vote on whether the benefits of Moderna's flu vaccine outweigh its risks in older adults, after regulators reversed course on reject
These 3 Stocks Have Crushed the Market This Year. Here's Why There Is More Upside Ahead
01:30am, Thursday, 18'th Jun 2026
Moderna is racing towards important clinical and regulatory catalysts. Krystal Biotech still has a large market to address in its core area.
MRNA Stock Jumps as FDA Briefing Docs Ease Flu Shot Approval Concerns
12:16pm, Wednesday, 17'th Jun 2026
Moderna jumps after FDA briefing documents on mFlusiva appear more constructive than expected ahead of a key advisory panel review.
Moderna (MRNA) Surges 6.3%: Is This an Indication of Further Gains?
10:15am, Wednesday, 17'th Jun 2026
Moderna (MRNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in th
FDA Panel Set To Debate Moderna Flu Shot
08:23am, Wednesday, 17'th Jun 2026
The U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) will meet on Thursday, June 18, to discuss approval of Moderna Inc.'s (NASDAQ:MRNA) e
Moderna to Host Investor Event - Science Day
07:00am, Wednesday, 17'th Jun 2026
CAMBRIDGE, MA / ACCESS Newswire / June 17, 2026 / Moderna, Inc. (Nasdaq:MRNA) today announced that it will host its Investor Event - Science Day at 9:00am ET on Thursday, June 25, 2026. The event will
Moderna interested in Germany production, sees opportunity in BioNTech closures, says CEO
02:38am, Wednesday, 17'th Jun 2026
U.S. pharmaceutical company Moderna is interested in investing in production facilities in Germany, with an eye on plants that its German rival BioNTech plans to close, CEO Stepha
Moderna Is Up 94% This Year: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?
03:21pm, Tuesday, 16'th Jun 2026
Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is jumping again.
Moderna Strengthens Commercial Strategy As Pipeline Advances
12:56pm, Tuesday, 16'th Jun 2026
Moderna Inc. (NASDAQ:MRNA) announced changes to its operating model and leadership structure. The biotechnology company is preparing for potential new product launches and advancing a broad pipeline.
